Brief Summary
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Intervention / Treatment
- Drug: AZD2287
- Drug: AZD2275
- Drug: AZD2284
Inclusion Criteria:
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status of 0 or 1.
- Histologically confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of adenocarcinomacancer arising from mucus-producing glands in organs of the prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation or neuroendocrine differentiated prostate cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs.
- Must have had prior bilateralaffecting both sides orchiectomyremoval of one or both testicles, also known as orchidectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).
- At least one metastatic lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imagingtests that create detailed images of areas inside the body (MRI), or bone scana type of medical imaging that uses a radioactive tracer to detect bone conditions or abnormalities obtained ≤ 28 days prior to the first dosethe amount of medication taken of Investigational Medicinal Product (IMP). Participants may have non-measurable lesions including bone only metastases.
- Adequate organ function